Update your tester profile Login
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Refer Your Friends & Family to Participate

    Simply help us get the word out about Prism Clinical Research and we’ll give you $100 for every friend you refer that completes a study.

    It’s that easy! Make money with each referral, and there’s no limit to how many friends you can refer!

    Rules:

    • Subject must complete the study.
    • Subject may not be referred more than one time.
    • Subjects may not refer each other.
    • Subject must complete the study before payment can be received.
    • Subjects eligible for Referral: (1) Must not be in Prism Clinical Research database; (2) Must not have participated in any study at Prism.
    • In the event that a subject is referred by multiple people, the first person who referred will receive payment.
    • Eligibility will be determined by Prism. Prism reserves the right to revise or eliminate this program at any time without notice.

     

     

  • Diagnosed with Liver Impairment?

    Prism Research has upcoming studies for individuals diagnosed with liver impairment.  These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.

     

    If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

    The current study we have available is Study 1702!

  • Study 1620: Male and Female Participants with Nasal Polyps

    Research Purpose: Study 1620 is designed to determine the safety and tolerability of an investigational drug being developed for the treatment of Chronic Rhinosinusitis with Nasal Polyps.

    *Must be diagnosed with Nasal Polyps to participate in this study*


    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women may participate if they meet one of the following criteria: postmenopausal, hysterectomy and/or bilateral oophorectomy, medically confirmed ovarian failure, tubal ligation or bilateral salpingectomy.

    Age

    18-65 years

    Body Mass Index (BMI)

    Between 17.5 – 35.0 kg/m²

    Tobacco/Nicotine Use

    Must be willing to abstain from tobacco and/or nicotine containing products for 24 hours prior to dosing and during the clinic stay.

    Health History

    Must be healthy; with the exception of diagnosed nasal polyps and chronic rhinosinusitis.

    Restricted Medications

    All medications will be reviewed for inclusion prior to screening.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 12 months.

    Clinic Stay

    • Participants will admit to Prism Clinical Research one-time for 2 overnights

    Clinic Visits

    • There are up to 13 follow-up clinical visits

     

    Compensation for participation time:   Up to $1,860                           


    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1702: Participants with Reduced Liver Function

    Research Purpose: Study 1702 is designed to evaluate bacteria in the digestive system and different methods of stool sample collection. No investigational drug will be administered. Participants will collect 8 stool samples from 4 different bowel movements over the course of 10 days. 

     Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate

    Age

    18-75 years

     

    Study Time Commitment: Study participation will last for approximately 10 days.

    Outpatient Visits

    • There are a total of 3 outpatient visits including screen

     

    Compensation for participation time:   Up to $410.00                     

    For information regarding this study contact Dayna at 651-724-5047 or email daynas@prismresearchinc.com

  • Study 1703:Healthy Participants Who Have Experienced episodes of cold sores due to Herpes Simplex Virus Type 1 infection

    Research Purpose: Study 1703 is a study to evaluate immune response in subjects infected with Herpes Simplex Virus Type 1 (HSV-1).

     *Must have experienced episodes of cold sores due to HSV-1 *

    For information regarding this study contact Lindsay: 651-362-3360 or lindsayd@prismresearchinc.com

     Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not pregnant or breastfeeding are allowed to participate.  Women of childbearing potential must agree to use approved birth control while in the study and for a period of one month after study completion.

    Age

    18-64 years

    Body Mass Index (BMI)

    Between 18-35 kg/m²

    Tobacco/Nicotine Use

    Nicotine use is permitted

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    Therapy with glucocorticoid or immunosuppressants 4 weeks prior to screening or anti-viral therapy any time in the past 12 months

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 12 weeks.

    In-clinic Stay

    • There are no in-clinic stays required for this study

    Out-clinic Visits Group A

    • There is one screening visit and 3 visits at the clinic

    Out-clinic Visits Groups B and C

    • There is one screening visit and one visit at the clinic

    Compensation for participation time:   Group A up to $340.00; Groups B & C up to $170.00

                           

    For information regarding this study contact Lindsay: 651-368-3360 or lindsayd@prismresearchinc.com

     

Glossary of Terms

  • Clinical Trial/Study: Any investigation in human subjects intended to discover or verify the clinical, pharmacological, and or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse reactions to an investigational product(s) and/or to study absorption, distribution, metabolism and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy. The terms clinical trial and clinical study are synonymous.

  • HIPAA: HIPAA is the acronym for the Health Insurance Portability and Accountability Act of 1996. The Centers for Medicare & Medicaid Services (CMS) is responsible for implementing various unrelated provisions of HIPAA. They are required to establish national standards for electronic health care transactions and national identifiers for providers, health plans, and employers. It also addresses the security and privacy of health data.

  • Informed Consent Form (ICF): A document approved by an authorized Institutional/Independent Review Board by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject’s decision to participate.

  • Informed Consent: A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject’s decision to participate. Informed consent is documented by means of a written, signed, and dated informed consent form.

  • Institutional/Independent Review Board (IRB): And independent body constituted of medical, scientific, and nonscientific members, whose responsibility it is to ensure the protection of the rights, safety and well-being of human subjects involved in a trial by, among other things, reviewing, approving, and providing continuing review of trials, protocols, amendments, and methods and materials to be used in obtaining and documenting informed consent of the trial subjects.

  • Investigational Product: A pharmaceutical form of an active ingredient or placebo being tested or used as a reference n a clinical trial including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication or when used to gain further information about an approved use.

  • Investigator: A person responsible for the conduct of the clinical trial at the trial site. If a team of individuals at a trial site conducts a trial, the investigator is the responsible leader of the team and may be called the Principal Investigator.
  • Protocol: A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial.

  • Randomization: The process of assigning trial subjects to treatment or control groups using and element of chance to determine the assignments in order to reduce bias.

  • Sponsor: An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical trial.

  • Subject/Participant/Volunteer: An individual who participates in a clinical trial, either as a recipient of the investigational product(s) or as a control.

 

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel